Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released its latest CEO Corner segment featuring CEO Brad Hauser. The segment discusses two key updates: the company's recent longer-term post hoc analysis from its first-in-human proof-of-concept study (PoC 1) and progress towards U.S. clinical trials scheduled to begin in 2026.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AMIX declined NaN%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
THE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis from its first-in-human proof-of-concept study (“PoC 1”) and recent progress made towards the start of U.S. clinical trials, on track to begin in 2026.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
When will Autonomix Medical (AMIX) begin its U.S. clinical trials?
What did Autonomix Medical's CEO discuss in the latest CEO Corner segment?
Where can investors find Autonomix Medical's latest CEO Corner segment?
What is Autonomix Medical's (AMIX) main business focus?
